Today's Top SOA Links
From the Wires
Breckenridge Announces Approval of Rizatriptan Benzoate Tablets
By: PR Newswire
Dec. 30, 2012 10:00 AM
BOCA RATON, Fla., Dec. 30, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Rizatriptan Benzoate Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA) for this product, which is being manufactured and supplied by Natco Pharma Limited, and will be available in both 5mg and 10mg strengths. Rizatriptan Benzoate Tablets are AB rated to Maxalt®, a $320 million dollar brand drug marketed by Merck. Maxalt® is a prescription medicine indicated for the acute treatment of migraines.
SOURCE Breckenridge Pharmaceutical, Inc.
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week